 |
市场调查报告书
商品编码
1198199
报告基因检测市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)Reporter Gene Assay Market - Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
报告基因检测市场预计在预测期内（2022 年至 2027 年）以 10.1% 的复合年增长率增长。
在 COVID-19 中，由于世界各地 COVID-19 病例的增加以及对疫苗和治疗药物的需求不断增长，预计报告基因检测市场将扩大。. 为 COVID-19 患者开发疫苗以及人们对诊断的需求不断增加，预计将为报告基因检测市场创造有利可图的机会。 此外，对 COVID-19 病毒的研究越来越多，研究其核酸结构以生产合适的候选疫苗，导致产品批准和推出激增。 例如，2021 年 8 月，Creative Diagnostics 将针对广泛的冠状病毒种类推出慢病毒 SARS-CoV-2 假病毒。 不同的载体可以表达不同的报告基因，例如 EGFP 或荧光素□，从而允许采用不同的方式监测病毒进入宿主细胞。 预计 COVID-19 将对市场增长产生重大影响，因为这些发布将推动与 COVID-19 相关的研究和开发。
此外，对基于细胞的分析的日益偏爱是报告基因分析市场增长的主要驱动力之一。 这是由于在生命科学研究和生物製造中越来越多地使用报告基因检测。 报告基因检测是研究健康细胞和患病细胞的生物化学和生理学的重要实验工具。 因此，报告基因检测在新发传染病病毒的研究和药物疗法的开发中受到了极大的关注。 此外，由于慢性遗传病和传染病在人群中普遍存在，因此有望将细胞应用于药物发现，报告基因检测的需求也在增加。 根据 2022 年世界卫生组织的一份报告，癌症等慢性病是全球主要死因之一，2020 年占死亡人数的近六分之一。 美国国家人类基因组研究所 2020 年 1 月发布的一份报告称，估计有 6,800 多种罕见病影响着 25 至 3000 万美国人。 因此，罕见病和遗传病的发病率不断增加，加上对早期诊断和有效治疗过程的需求不断增加，预计将推动市场增长。
此外，市场参与者采取的战略举措也有望推动市场增长。 例如，2021 年 12 月，诺华收购了英国眼科基因治疗公司 Gyroscope Therapeutics 的全部股权。 此次收购帮助诺华公司将其产品组合扩展到基因治疗领域。
因此，由于上述因素，市场预计在预测期内会出现增长。 然而，基于细胞的研究的高成本可能会阻碍市场增长。
报告基因检测市场趋势
在报告基因检测市场，检测试剂盒有望占据主要市场份额
预计在预测期内，检测试剂盒部分将产生可观的收入。 COVID-19 的突然爆发增加了对报告基因检测的需求，以研究未知病毒的基因表达并确保正确接种疫苗。
主要使用的有荧光蛋白相关检测试剂盒、分泌型碱性磷酸□（SEAP）检测试剂盒、荧光素□检测试剂盒、β-半乳糖甘□检测试剂盒等。 这是因为它们越来越多地用于研究基因转录和翻译水平的表达以及分析信号转导通路。 此外，多项检测可确保准确的信号测量和一致的结果。 此外，该测定方便、快速、灵敏，并显示出广泛的检测线性模式。 此外，对建立基于细菌细胞的报告系统的 β-半乳糖甘□高通量检测的研究兴趣不断增加，这也促进了检测试剂盒领域的最快增长。 因此，对检测试剂盒领域的需求激增预计将推动市场增长。
此外，市场进入者推出的检测试剂盒也推动了该领域的发展。 例如，2021 年 6 月，QIAGEN 将推出 QIAprep&CRISPR 试剂盒，使研究人员能够以无与伦比的速度和效率分析编辑过的遗传物质，以确定他们的干预措施如何改变 DNA 序列的功能。并推出 CRISPR Q-Primer Solutions。
因此，由于上述因素，预计该细分市场将推动市场增长。
北美将占据很大的市场份额，预计在预测期内也会如此。
由于用于疾病检测的诊断和报告基因检测产品的创新，北美地区将主导全球市场。 预计该地区将在预测期内保持其主导地位，生物技术公司和医疗设施的投资将加速基因治疗的发展。
生物技术和製药公司增加投资以建立专门研究和製造基因疗法及相关基因产品的设施，这也促进了市场的增长。 例如，2020 年 12 月，Taisha Gene Therapies, Inc. 将在北卡罗来纳州达勒姆开设一个约 187,000 平方英尺的现有商业规模设施，用于其基因治疗管线的临床前、临床和商业生产。我们已经签订了一项租用和配置符合良好生产规范 (cGMP) 的製造设施。 此外，2021 年 12 月，辉瑞（Pfizer）宣布在北卡罗来纳州达勒姆开设一个新的最先进的临床製造工厂。 该设施扩展了辉瑞在基因治疗方面的端到端能力，并建立在公司在北卡罗来纳州的现有足蹟之上。 达勒姆工厂将支持辉瑞在基因治疗研发和製造方面的持续投资，过去六年投资8亿美元建设三个高度可扩展的、最先进的基因治疗製造设施，是建设的一部分.
此外，该地区推出的检测试剂盒等产品也推动了市场增长。 例如，2021 年 11 月，Bio-Techne 品牌 Asuragen, Inc. 推出了一种新试剂盒，用于检测 CFTR 基因中的致病变异，即 AmplideX PCR/CE CFTR 试剂盒，仅供研究使用。 该产品比市场上任何其他 CFTR 检测方法更广泛地覆盖美国不同人群。 这些专门针对美国人口的产品也在推动市场增长。
因此，由于上述因素，预计北美地区的市场在预测期内将出现增长。
报告基因检测市场竞争者分析
报告基因检测市场竞争激烈，由几家主要参与者组成。 从市场份额的角度来看，一些主要参与者目前主导着市场。 目前的市场主导者包括 Thermo Fisher Scientific、Puritan Medical Products、Trinity Biotech、Medical Wire & Equipment、Vircell、Quidel Corporation、BD、Titan Biotech Limited、Copan Diagnostics、EKF diagnostics、Hardy Diagnostics、Pretium Packaging 等。
其他福利。
- Excel 格式的市场预测 (ME) 表
- 三个月的分析师支持
内容
第1章介绍
- 研究假设和市场定义
- 调查范围
第2章研究方法论
第 3 章执行摘要
第4章市场动态
- 市场概览
- 市场驱动因素
- 增加对细胞研究的资助
- 对基于细胞的检测的偏好不断上升
- 市场製约因素
- 基于细胞的研究成本高
- 波特的五力分析
- 新进入者的威胁
- 买方/消费者议价能力
- 供应商的议价能力
- 替代品的威胁
- 竞争公司之间的敌对关係
第 5 章市场细分
- 按产品分类
- 检测试剂盒
- 试剂
- 通过申请
- 基因调控
- 细胞信号通路
- 其他
- 按地区
- 北美
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东
- 海湾合作委员会
- 南非
- 其他中东地区
- 南美洲地区
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第6章竞争格局
- 公司简介
- Thermo Fisher Scientific
- PerkinElmer Inc.
- Merck KGaA
- Bio-Rad Laboratories Inc.
- Cell Signaling Technologies Inc.
- Promega Corporation
- New England Biolabs
- Cell Biolabs Inc.
- Eurofins DiscoverX products
- Biotium
- InVivoGen
第7章 市场机会与今后动向
The reporter gene assay market is projected to register a CAGR of 10.1% during the forecast period (2022-2027).
Amidst COVID-19, the reporter gene assay market is expected to grow owing to the rising cases of COVID-19 among people across the globe and the rising demand for vaccines and treatment drugs. The increase in the need for the development of vaccines for COVID-19 infected patients and the diagnosis of people is projected to create lucrative opportunities for the reporter gene assay market. Also, the increasing research on the COVID-19 virus to study the nucleic acid structure to produce suitable vaccine candidates has led to a surge in product approvals and launches. For instance, in August 2021, Creative Diagnostics launched a variety of lentiviral SARS-CoV-2 pseudoviruses from a wide range of coronavirus species. Different vectors can be used to express different reporters such as EGFP or luciferase, allowing the monitoring of viral entry into host cells by a variety of means. Such launches are expected to propel the research and development related to COVID-19 and, thus, COVID-19 is expected to have a significant impact on the growth of the market.
Moreover, the growing preference for cell-based assays is one of the major driving factors for the growth of the reporter gene assay market. This is due to the increasing usage of reported gene assays in life science research and biomanufacturing. The reporter gene assays are a crucial experimental tool to study the biochemistry and physiology of both healthy and diseased cells. Thus, the reporter gene assays gained much attention in studying emerging infectious viruses and developing drug therapies. Additionally, the increasing prevalence of chronic genetic disorders and infectious diseases among the population has led to increased demand for reporter gene assays owing to the cell-based applications in drug discovery. According to a World Health Organization report in 2022, chronic diseases such as cancer are one of the leading causes of death worldwide, accounting for nearly one in six deaths in 2020. The National Human Genome Research Institute report published in January 2020 stated that more than 6,800 rare diseases affect an estimated 25 to 30 million Americans. Therefore, the increasing incidences of rare and genetic disorders coupled with increasing demand for early diagnosis and effective treatment processes are expected to boost the growth of the market.
Additionally, the strategic initiatives undertaken by the market players are also expected to propel the growth of the market. For instance, in December 2021, Novartis acquired all share capital of the United Kingdom-based ocular gene therapy company Gyroscope therapeutics. This acquisition helped the company, Novartis, extend its portfolio into gene therapy.
Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, the high cost of cell-based research may hinder the growth of the market.
Reporter Gene Assay Market Trends
The Assay Kits Segment is Expected to Hold a Major Market Share in the Reporter Gene Assay Market
The assay kits segment is expected to register significant revenue over the forecast period. The sudden outbreak of COVID-19 has increased the demand for reporter gene assays owing to their efficiency in studying the gene expression of the unknown virus to produce suitable vaccination.
The assay kits mostly used are fluorescent protein-related assay kits, secreted alkaline phosphate(SEAP) assay kits, luciferase assay kits, beta-galactosidase assay kits, and others. This is attributed to their increased usage in expression studies and signaling pathway analysis during gene transcription or translation levels. Also, the extensive usage of assays enables precise signal measurement, maintaining the consistency of the outcomes. In addition, they are convenient, fast, sensitive, and display a broadly linear pattern for detection. Moreover, the rising focus of researchers on establishing high-throughput assays of beta-galactosidase for reporter systems based on bacterial cells contributes to the fastest growth rate of the assay kit segments. This huge surge in demand for the assay kits segment is expected to propel the market's growth.
The launch of assay kits by market players is also propelling the growth of the segment. For instance, in June 2021, QIAGEN launched the QIAprep& amp; CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence.
Thus, owing to the abovementioned factors, the market segment is expected to propel the growth of the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.
The North American region is likely to dominate the global market owing to the technological innovations in the diagnostic and reporter gene assay products used for disease testing. The region will retain its dominant position over the forecast years on account of investments by biotechnology companies and health care facilities to accelerate the development of gene therapies.
The growing investment by biotechnological and pharmaceutical companies in establishing facilities dedicated to research and manufacturing of gene therapy and related genetic products also drives the growth of the market. For instance, in December 2020, Taysha Gene Therapies, Inc. entered into a lease agreement to occupy and configure an approximately 187,000-square-foot commercial-scale current Good Manufacturing Practices (cGMP) manufacturing facility in Durham, North Carolina for preclinical, clinical, and commercial production of its gene therapy pipeline. Additionally, in December 2021, Pfizer Inc. reported the opening of a new, state-of-the-art clinical manufacturing facility in Durham, North Carolina. The facility expands Pfizer's end-to-end capabilities in gene therapy and builds on the company's existing footprint in North Carolina. The Durham facility is part of a USD 800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer's continued investment in gene therapy research, development, and manufacturing.
In addition, the launch of products such as assay kits in the region is also propelling the growth of the market. For instance, in November 2021, Asuragen, Inc., a Bio-Techne brand, launched a new kit to detect pathogenic variants in the CFTR gene, namely the AmplideX PCR/CE CFTR kit, intended for research use only. It provides broader coverage of the diverse United States population than any other commercially available, targeted CFTR testing assay. Such products, specifically targeting the United States population, are also propelling the growth of the market.
Thus, owing to the abovementioned factors, the market in the North American region is expected to show growth over the forecast period.
Reporter Gene Assay Market Competitor Analysis
The Reporter Gene Assay Market is competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some companies currently dominating the market are Thermo Fisher Scientific, Puritan Medical Products, Trinity Biotech, Medical Wire & Equipment, Vircell, Quidel Corporation, BD, Titan Biotech Limited, Copan Diagnostics, EKF diagnostics, Hardy Diagnostics, Pretium Packaging, and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing funding for Cell-based research
- 4.2.2 Growing preferences of Cell- based assays
- 4.3 Market Restraints
- 4.3.1 High cost of the cell-based research
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Product
- 5.1.1 Assay Kits
- 5.1.2 Reagents
- 5.2 By Application
- 5.2.1 Gene Regulation
- 5.2.2 Cell signalling pathways
- 5.2.3 Others
- 5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
- 5.3.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Thermo Fisher Scientific
- 6.1.2 PerkinElmer Inc.
- 6.1.3 Merck KGaA
- 6.1.4 Bio-Rad Laboratories Inc.
- 6.1.5 Cell Signaling Technologies Inc.
- 6.1.6 Promega Corporation
- 6.1.7 New England Biolabs
- 6.1.8 Cell Biolabs Inc.
- 6.1.9 Eurofins DiscoverX products
- 6.1.10 Biotium
- 6.1.11 InVivoGen
